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Abstract
Background: Women with breast cancer who have multiple affected relatives are more likely to have inherited
genetic risk factors for the disease. All the currently known genetic risk factors for breast cancer account for less
than half of the average familial risk. Furthermore, the genetic factor(s) underlying an increased cancer risk for many
women from multiple-case families remain unknown. Rare genomic duplications and deletions, known as copy
number variants (CNVs), cover more than 10% of a human genome, are often not assessed in studies of genetic
predisposition, and could account for some of the so-called “missing heritability”.
Methods: We carried out a hypothesis-generating case-control study of breast cancer diagnosed before age
40 years (200 cases, 293 controls) using population-based cases from the Australian Breast Cancer Family Study.
Genome-wide scanning for CNVs was performed using the Human610-Quad BeadChip and fine-mapping was
conducted using PennCNV.
Results: We identified deletions overlapping two known cancer susceptibility genes, (BRCA1 and BLM), and a
duplication overlapping SMARCB1, associated with risk. The number of deletions across the genome was 1.5-fold
higher for cases than controls (P = 10-16), and 2-fold higher when only rare deletions overlapping genes (frequency <1%)
were assessed (P = 5 × 10-4). Association tests of CNVs, followed by experimental validation of CNV calls, found deletions
overlapping the OR4C11 and OR4P4 genes were associated with breast cancer (P = 0.02 and P = 0.03, respectively).
Conclusion: These results suggest rare CNVs might have a role in breast cancer susceptibility, at least for disease at a
young age.
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Background
Breast cancer is the most common malignancy among
women in the developed world, and is increasing rapidly
in the developing world. A proportion of women with
breast cancer have multiple affected relatives and are
therefore more likely to have inherited genetic factors
that increase their risk of developing the disease. All the
currently known genetic risk factors for breast cancer
currently only account for around 48% of average famil-
ial risk, and account for a lower proportion of the famil-
ial risk of disease at a young age, and the vast majority
of women from multiple-case families do not have a
known genetic explanation for their increased cancer
risk [1, 2]. Thus, for a substantial fraction of women, in-
cluding young affected women and those with a family
history, the cause of their disease remains unexplained.
Copy number variants (CNVs) are estimated to cover
5–10% of the human genome [3] and, based on nucleotide
coverage, are responsible for the majority of genetic vari-
ability in human populations. CNVs have been reported to
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disrupt genes known to be involved in breast cancer sus-
ceptibility, including BRCA1, BRCA2, TP53 and CHEK2
[4], and could similarly alter other genes involved in path-
ways related to breast cancer susceptibility. Furthermore,
several array-based studies have reported candidate rare
CNVs that overlap genes; variants in these might contrib-
ute to breast cancer susceptibility [5–7]. However, there
has been a notable lack of consistency across these studies,
probably because many women carry rare CNVs or be-
cause of false CNV calls caused by technical issues [8].
Evidence from some studies has suggested that the fre-
quency and size of germline CNVs are increased in
women with breast cancer [5, 7, 9], and that this
might be strongest for CNVs that overlap gene re-
gions [5, 7]. Thus, functional disruption of genes by
CNVs across the genome might contribute to the
genetic basis of breast cancer risk.
Only a few studies have examined the relationship be-
tween common germ-line CNVs and breast cancer risk.
A large genome-wide association study (2000 breast can-
cer cases and 3000 controls) from the Wellcome Trust
Case Control Consortium suggested that such CNVs
were unlikely to have a major role in the genetic basis of
breast cancer [10]. However, more recent genome-wide
association studies of common CNVs (mean allele fre-
quency (MAF) ≥5%) in Chinese and European women
identified a deletion in the APOBEC3 gene cluster asso-
ciated with up to 1.3-fold and up to 2.3-fold increase in
risk of breast cancer associated with hemizygous and
homozygous deletions, respectively [11, 12].
To better understand the role of CNVs in breast can-
cer risk we have conducted a hypothesis-generating
study of breast cancer at a young age (diagnosed before
the age of 40 years). Our study aimed to assess whether
CNVs across the genome are more frequent in such
breast cancer cases when compared with unaffected
controls, and whether cancer susceptibility genes are
disrupted by rare CNVs.
Methods
Subjects
We conducted a hypothesis-generating study of 258
women who were diagnosed with breast cancer before
the age of 40 years from the population-based Australian
Breast Cancer Family Study [13–15]. These cases had
been previously screened for germline mutations in
BRCA1, ATM, CHEK2, PALB2, TP53, BRCA2, CDH1,
and FANCM [13, 14, 16–25]. A total of 348 women un-
affected with breast cancer (controls) were selected from
participants in the Australian Mammographic Density
Twins and Sisters Study, a cross-sectional study of twins
and their sisters [15, 26]. All study participants provided
written informed consent.
Genotyping and identification of CNVs
All DNA samples were genotyped with the Human610-
Quad BeadChip (Illumina, Inc, San Diego, CA, USA)
with approximately 610,000 markers (including approxi-
mately 20,000 non-polymorphic markers) for single nu-
cleotide polymorphism (SNP) and CNV analysis. Samples
were processed using Illumina’s recommended protocol
for Infinium HD assays. Data for each array were normal-
ised using GenomeStudio 2011.1 software (Illumina).
Probe information, including genomic location, signal in-
tensity (Norm R), allele frequency (Norm theta), log R ra-
tios (LRRs), and B allele frequencies (BAF), for each
sample was calculated and exported from GenomeStudio.
All samples had a call rate >95%. The CNV calls were gen-
erated using the PennCNV program (version 27 Aug.
2009), using the default program parameters, library files,
and genomic wave adjustment.
Quality control procedures were performed to remove
poor-quality array data (Additional file 1: Figure S1).
Samples were excluded if they met the following criteria:
log R ratio standard deviation >0.28; B allele frequency
drift >0.01; waviness factor deviating from 0 by >0.04, or
with the number of CNV calls exceeding 70. To reduce
false positives, CNV calls were excluded if they con-
tained <5 probes, and/or were ≥1000 kb in size. A total
of 200 cases and 293 controls passed quality control
steps and were assessed in the study. CNV data used in
the study are shown in Additional file 2: Table S1.
Identification of genes overlapping CNVs and defining
rare CNVs
To avoid examining multiple isoforms from genes, we
annotated 39,544 UCSC RefSeq (NCBI36/Hg18) tran-
scripts using the SOURCE database [27] and defined the
genomic intervals for a total of 18,791 unique genes.
Thus, each gene interval encompassed the start and end
of all associated RefSeq transcripts (Additional file 1:
Figure S2). CNVs and gene regions that were estimated
to overlap by at least one base pair were identified in a
genome-wide scan using Intersect and Join tools from
the Galaxy web server [28–30].
Because putative CNV calls do not typically conform to
discrete genomic regions in different women, we used the
genome coordinates of 18,791 RefSeq gene (NCBI36/Hg18)
boundaries to define a CNV region (Additional file 1:
Figure S1). Each of these regions therefore represented a clus-
ter of one or more CNVs overlapping a well-characterised
gene in the human genome and was used to measure the
frequency of CNVs in our study. Rare CNVs were defined as
those with a frequency <1% in the total sample.
CNV validation by quantitative PCR
DNA samples were used to experimentally validate
putative CNVs at 12 genomic regions using Human
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TaqMan® Copy Number Reference Assays (Thermo-
fisher Scientific Inc). Primer and probe sequences are
presented in Additional file 3: Table S2. RNaseP was
used as an endogenous reference gene. All assays
were carried out in triplicate.
Statistical analysis of CNV load
Welch’s t test was conducted to establish the level of sig-
nificance associated with the difference in CNV carrier
frequencies between the cases and controls. This test is
an adaptation of Student’s t test designed to cope with
datasets that have unequal variances. The statistical
package R version R 2.14.2 was used to perform statis-
tical analyses. P values <0.05 were considered significant.
Genome-wide CNV association analysis
Genes overlapping CNVs identified in cases or controls
were assigned as having DNA loss (copy number states
zero or one) or DNA gain (copy number states three or
four). Perl 5.14.2 (ActiveState, Canada) was used to pro-
duce counts of the CNVs based on copy number state
and the gene region by which they were defined. The
CNV state with the most CNVs for each region was
identified. A corresponding table of incidence of the
most numerous CNV state in that region was analysed
between cases and controls using Fisher’s exact test. This
was used to calculate odds ratios, 95% confidence inter-
vals and P values for the association between each CNV
and cancer status. P values were adjusted for multiple
testing with a false discover rate of 5%, using the method
of Benjamini and Yekutieli (2001). Tests with a corrected
P value <0.05 were considered statistically significant.
The analysis was performed based on CNVs defined by
their location within a gene region.
Results
CNV discovery in cases of early-onset breast cancer and
in controls
A total of 58 cases and 55 controls were removed from
the study after quality control criteria were applied, leav-
ing 200 cases and 293 controls for downstream analyses
(Additional file 1: Figure S1). Using PennCNV software,
a total of 5109 and 6133 CNV calls were generated for
cases and controls, respectively, ranging from 0.6 to
998 kb. The average number of CNVs observed in the
two study groups was larger in cases than controls (25.6
vs. 20.9; P = 2 × 10-10) (Table 1). When accounting for
copy number type, the average number of deletions
was 1.5-fold greater in cases compared with controls
(18.1 vs. 12.4; P = 2 × 10-16), whereas the average num-
ber of copy number gains in cases was slightly lower
than that of controls (7.4 vs. 8.5; P = 0.01). These re-
sults suggest that women with early-onset breast can-
cer carried a greater CNV load across the genome
compared with controls and that this feature was due
to the inheritance or de novo formation of genomic
deletions.
To assess the potential disruption of CNVs to func-
tional regions across the genome, CNVs overlapping
18,791 reference sequence (RefSeq) genes (NCBI36/
Hg18) were identified in cases and controls. Thirty-four
percent of CNVs were predicted to overlap genes in both
study groups (Table 1). Deletions affecting gene regions
were shown to be 1.6-fold more frequent in cases com-
pared to controls (5.2 vs. 3.3; P = 4 × 10-10). Concor-
dantly, the average number of RefSeq genes predicted to
be disrupted by genomic deletions was also 1.6-fold higher
in cases compared with controls (7.3 vs. 4.7; P = 2 × 10-8).
By comparison, there was no significant difference ob-
served between cases and controls when the number of
copy number gains overlapping genes (P = 0.1), and the
number of genes overlapping copy number gains (P = 0.5)
were measured.
To determine whether CNV size contributed to gen-
omic burden we calculated the genomic distance be-
tween the start and end probes of each PennCNV call.
These data showed that there was a slight decrease in
the average size of CNVs in cases compared with con-
trols (59.4 kb vs. 65.7 kb; P = 0.001); however, there was
no statistically significant difference in the average size
of the CNVs between the groups when considering copy
number type (deletion or duplication) (Table 2). Thus,
the enrichment of genes disrupted by genomic deletions
in cases of early breast cancer is the result of increased
frequency rather than the size of these variants.
Rare CNVs in cases of early-onset breast cancer and in
controls
To examine the prevalence of rare CNVs, RefSeq gene
regions containing five or more CNVs (>1% frequency in
the study cohort) were excluded from downstream ana-
lyses. By this process, all remaining rare CNVs assessed
in this study overlapped RefSeq gene regions. The num-
ber of rare deletions in the cases were twofold greater
than in controls (1.6 vs. 0.8; P = 5 × 10-4), but there was
no statistically significant difference in copy number
gains between the two groups (P = 0.6) (Table 3). The
average number of RefSeq genes predicted to be dis-
rupted by genomic deletions was 1.8-fold higher in cases
compared with controls (2.0 vs. 1.2; P = 5 × 10-3). The ra-
tio of genes disrupted per rare deletion event in each
sample was 1.2 in cases and 1.4 in controls (data not
shown). There was no significant difference in ratios be-
tween the two groups (P = 0.1). Together these results
suggest that in most samples rare deletions are disrupt-
ing a single gene, and such events in cases of early-onset
breast cancer were twice as common as in controls.
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Rare CNVs disrupting known cancer susceptibility genes
Annotation of CNVs in cases and controls against genes
known to be involved in cancer-associated syndromes
(Additional file 3: Table S3) revealed four cases with dele-
tions in APC (n = 2), BRCA1 (n = 1) and BLM (n = 1), and
one case with a duplication overlapping SMARCB1 (n = 1).
One control was also found to harbour a putative deletion
overlapping APC (Fig. 1). Subsequent evaluation with
qPCR confirmed deletions overlapping BLM and BRCA1,
the duplication overlapping SMARCB1, but none of
the deletions overlapping the APC locus (two cases
and one control) (Additional file 3: Table S4). Each
validated CNV was shown to overlap one or more of
the coding exons within the respective cancer suscep-
tibility gene, suggesting a deleterious effect on the
encoded proteins. CNVs potentially associated with
risk of breast cancer did not overlap any of the genes
that are commonly included in breast cancer predis-
position gene panel tests (Additional file 4: Table S5).
The BLM deletion was genotyped in relatives of the
affected proband and identified two additional carriers
of deletion but none were affected with breast cancer
and an (obligate) non-carrier of this deletion had had
breast cancer diagnosed at age 42 years (Additional
file 1: Figure S3).
Genome-wide CNV association study
To identify other new genomic loci contributing to
breast cancer, we applied a gene-centric-based approach
that defines copy number events by their location within
a RefSeq gene region and compares the frequency of
these events in cases and controls. Thus, genes overlap-
ping CNVs identified in case and control cohorts were
subsequently assigned status as DNA loss or DNA gain.
The odds ratio estimates for the association between
CNV status and risk of breast cancer are presented in
Table 4. Deletions in three genes were associated with
increased risk of breast cancer (DOCK5, P = 3 × 10-3;
OR4C11, P = 2 × 10-2; and OR4P4, P = 3 × 10-2). qPCR
did not confirm the small 646-base-pair deletion at the
DOCK5 locus (Table 4). The CNV was predicted by six
probes mapping to a 1.4 kb simple tandem repeat region
(chr8:25,073,452-25,074,806; GRCh37/hg19). In contrast,
deletions were overlapping the ORC4C11 and OR4P4 loci
were verified by qPCR (Table 4; Additional file 3: Table S4).
Discussion
In comparison with the large amount of single nucleo-
tide variant data available from breast cancer studies, the
contribution of inherited copy number variation to
breast cancer risk remains relatively understudied. To
Table 2 Size of CNVs in breast cancer cases and controls across the whole genome, and overlapping genomic features
CNV
type
Mean size of CNVs (kb) Difference in means (kb) Case/control
ratio
P value
Cases (n = 200) Controls (n = 293) Case - controls 95% CI
All 59.4 65.7 -6.3 -10.1, -2.5 0.90 0.001
Deletions 42.9 42.7 0.2 -3.0, 3.4 1.00 0.89
Gains 10.1 10.0 0.1 -7.7, 10.3 1.01 0.77
CNV copy number variation
Table 1 Frequency of CNVs and overlapping genes in breast cancer cases and controls
Genomic
feature
Total count Mean frequency Difference in means Case/control
ratio
P value
Cases (n = 200) Controls (n = 293) Cases Controls Case - controls 95% CI
CNVs
All 5109 6133 25.6 20.9 4.6 3.2, 6.0 1.2 2e-10
Deletions 3622 3644 18.1 12.4 5.7 4.4, 7.0 1.5 2e-16
Gains 1487 2489 7.4 8.5 -1.1 -1.9, -0.3 0.9 0.01
CNVs overlapping genes
All 1734 2069 8.7 7.1 1.6 0.9, 2.4 1.2 3e-05
Deletions 1048 956 5.2 3.3 2.0 1.4, 2.6 1.6 4e-10
Gains 686 1113 3.4 3.8 -0.4 -0.8, 0.1 0.9 0.1
Genes overlapping CNVs
All 2816 3501 14.1 12.0 2.1 0.5, 3.8 1.2 0.01
Deletions 1450 1368 7.3 4.7 2.6 1.7, 3.5 1.6 2e-08
Gains 1366 2133 6.8 7.3 -0.5 -1.8, 0.9 0.9 0.5
CNV copy number variation
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our knowledge, this is the largest genome-wide CNV
analysis of early-onset (<40 years of age) breast cancer in
a population-based study. Our results suggest that CNV
frequency (or CNV load) may be associated with breast
cancer risk, which is consistent with non-statistically sig-
nificant data from a previous study of cases of familial
and early-onset (<40 years of age) breast cancer [5].
Moreover, our study showed that on average, women
with early-onset breast cancer carried one extra deletion
within their genome that overlapped a coding gene.
Consistent with our data, a recent analysis of the Ex-
ome Aggregation Consortium (ExAC) database showed
that the average human genome contains 2.1 rare
(<0.5%) CNVs (0.8 deletions, 1.3 duplications) that inter-
sect at least one protein-coding gene [31]. These results
are similar to those from controls analysed in this study
in which there were 2.6 rare (<1%) CNVs (1.2 deletions,
1.4 duplications) that intersect at least one protein-
coding gene. The slightly larger values seen in our study
might be explained by the less stringent criterion we
used for defining a rare CNV. A possible reason for the
larger number of deletions seen in the cases may be re-
lated to chemotherapeutic and/or radiological treatment
effects on patients. However, in contrast to deletions we
observed a reduced total number of duplications in cases
compared with controls, and no significant difference
between groups when assessing rare CNVs. Such a trend
is difficult to explain if the genomic rearrangements are
a result of treatment alone. Our results were not directly
comparable with results from three other breast-cancer-
related studies [5–7] that used a different and more
stringent approach to define rare CNVs, that is those
showing no overlap or minimal overlap with CNVs listed
in the Database of Genomic Variants.
Table 3 Frequency of rare CNVs (<1% frequency) and overlapping genes in breast cancer cases and controls
Genomic
feature
Total frequency Mean frequency Difference in means Case/control
ratio
P value
Cases (n = 200) Controls (n = 293) Cases Controls Case - controls 95% CI
Rare CNVs (<1%) overlapping genes
All 513 491 2.6 1.7 0.9 0.3, 1.5 1.5 0.002
Deletions 327 243 1.6 0.8 0.8 0.4, 1.3 2.0 0.0005
Gains 186 248 0.9 0.8 0.1 -0.2, 0.4 1.1 0.6
Genes overlapping rare CNVs (<1%)
All 778 749 3.9 2.56 1.3 0.0, 2.6 1.5 0.05
Deletions 403 337 2.0 1.2 0.8 0.3, 1.5 1.8 0.005
Gains 375 412 1.9 1.4 0.5 -0.6, 1.6 1.3 0.4
CNV copy number variation
Fig. 1 Putative copy number variation (CNV) calls overlapping known cancer susceptibility genes in five cases of early-onset breast cancer. UCSC Genome
Browser screenshots (NCBI36/hg18) show the location of the CNVs (solid red rectangles) in relation to each gene. RefSeq reference sequence
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Our study identified a deletion overlapping the known
breast cancer susceptibility gene, BRCA1, in a woman
diagnosed with infiltrating ductal carcinoma of the
breast (grade 3) at the age of 39 years, who did not have
a family history of the disease and did not have any rela-
tives participating in our study. A rare deletion overlap-
ping the Bloom syndrome RecQ-like helicase gene,
BLM, was also detected in a patient and some of her
family members. Although data were limited for segrega-
tion analysis, our results are consistent with the previous
finding that BLM mutations are associated with a per-
haps more moderate increased risk of breast cancer [32].
These data are consistent with this rare allele being asso-
ciated with a low-to-moderate risk of breast cancer but
our study did not have the capacity to formally address
or measure a possible link to breast cancer risk. No
other women in this study had CNV disruption to
cancer susceptibility gene(s). Thus, it remains unclear
whether the additional genes disrupted by rare deletions
in cases have a causal role in breast cancer risk.
A genome-wide association study of the cases and
controls identified deletions overlapping three gene
regions (DOCK5, 6.9-fold, P = 0.003; OR4C11, 2.6-fold,
P = 0.02, and OR4P4, 2.4-fold, P = 0.03) that were associ-
ated with an increased risk of breast cancer after account-
ing for multiple testing (Additional file 4: Table S5).
Assessment of these regions in a subset of samples using
orthogonal technology verified the deletions overlapping
the olfactory receptor genes, OR4C11 and OR4P4, but not
DOCK5. OR4C11 and OR4P4 are located at 11q11 and
have been previously found to overlap a common bi-allelic
deletion [33, 34]. Of note, deletions overlapping OR4C6
and OR4S2 that were not associated with breast cancer
risk after multiple testing (Table 4) are located adjacent to
the OR4C11/OR4P4 gene locus. To our knowledge, vari-
ants overlapping the OR4C11/OR4P4 gene locus have not
previously been shown to be associated with breast cancer
risk. It is unclear how this locus would have a causative
role in breast cancer development, although 11q deletions
are commonly found in breast tumours, particularly those
classified as having a high histological grade [35]. A
review of two breast tumour datasets from Pereira et al.
(n = 1980) and The Cancer Genome Atlas (n = 960)
showed that expression of OR4C11 and OR4P4 did not
correlate with copy number loss (data not shown) [36, 37],
although this locus may harbour regulatory element(s)
that control key genes from long range.
CNVs overlapping more than 100 genes have been
found exclusively or at a greater frequency in cases of fa-
milial and/or early-onset breast cancer; however, none of
these loci have been identified in more than one study
[8]. Large-scale studies of women with early-onset breast
cancer are now required to better understand the contri-
bution of germline CNVs to breast cancer risk. Such
CNV-based studies are now possible by utilising avail-
able SNP genotyping data generated by massive
genome-wide association studies that include cases of
early-onset breast cancer [38, 39].
Conclusions
We report that the frequency of rare CNVs may be asso-
ciated with breast cancer risk, and that compared with
controls, patients with early-onset breast cancer carried
one extra deletion within their genome that overlapped
a coding gene. A genome-wide analysis of CNVs identi-
fied deletions at the OR4C11/OR4P4 locus that were also
associated with breast cancer risk. Larger studies are re-
quired to further investigate these possible associations
to understand the role of CNVs in the development of
breast cancer.
Additional files
Additional file 1: Figure S1. Study design for CNV discovery, quality
control and analysis. Figure S2. The protocol use to define RefSeq gene
boundaries. Figure S3. BLM deletions identified in a familial breast cancer
pedigree. Male and female individuals are represented by squares and
circles, respectively. The index case patient, who underwent genome-wide
CNV profiling, is indicated by an arrow. Individuals with breast cancer are
represented by closed circles. Other cancers are indicated by black shading
in the lower left quadrant. Age at death, last known diagnosis or cancer
Table 4 Common copy number changes in RefSeq genes over-represented in early-onset breast cancer cases
Gene Type Cases (n = 200) Controls (n = 293) OR 95% CI P Padjust
a qPCR verifiedb
DOCK5 Deletion 29 7 6.9 2.9, 19.0 5 × 10-7 3 × 10-3 0% (0/4)
DOCK5 Gain 3 29 0.1 0.0, 0.5 1 × 10-4 NS 0% (0/4)
OR4C11 Deletion 71 51 2.6 1.7, 4.1 7 × 10-6 2 × 10-2 83% (5/6)
OR4P4 Deletion 82 66 2.4 1.6, 3.6 2 × 10-5 3 × 10-2 100% (8/8)
UGT2B17 Deletion 57 45 2.2 1.4, 3.5 6 × 10-4 NS Not tested
OR4C6 Deletion 62 50 2.2 1.4, 3.4 4 × 10-4 NS Not tested
OR4S2 Deletion 65 54 2.1 1.4, 3.3 4 × 10-4 NS Not tested
aMultiple testing with a false discovery rate of 5% using the method of Benjamini and Yekutieli. bPercentage of copy number variation (CNV) positive samples
tested (number of positive samples/number of samples tested). RefSeq reference sequence, CI confidence interval, NS not significant, OR odds ratio, qPCR
quantitative polymerase chain reaction
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diagnosis is indicated where known. Copy number genotype at the BLM
locus is noted as BLM deletion (BLM del) or wildtype (wt) copy number.
(DOCX 30 kb)
Additional file 2: Table S1. CNV data for cases and controls.
Chromosome coordinates given according to Hg18. (XLSX 819 kb)
Additional file 3: Table S2. Taqman assays used for CNV assessment at
7 gene loci. Table S3. Cancer-predisposing genes disrupted by rare CNVs.
Table S4. Results of Taqman assays carried across 7 gene loci. (DOCX 18 kb)
Additional file 4: Table S5. Results from a genome-wide association
analysis of CNVs overlapping gene loci. (XLSX 205 kb)
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